Wall Street Zen Upgrades Maze Therapeutics (NASDAQ:MAZE) to Hold

Maze Therapeutics (NASDAQ:MAZE) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other brokerages also recently weighed in on MAZE. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Truist Financial initiated coverage on shares of Maze Therapeutics in a research note on Tuesday, March 17th. They issued a “buy” rating and a $68.00 target price on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. HC Wainwright lifted their price target on shares of Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Wells Fargo & Company started coverage on Maze Therapeutics in a report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $64.11.

Maze Therapeutics Price Performance

MAZE opened at $30.38 on Friday. The firm has a market capitalization of $1.51 billion, a P/E ratio of -9.41 and a beta of 4.47. The company’s 50-day moving average is $45.61 and its 200 day moving average is $37.62. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.

Insiders Place Their Bets

In other Maze Therapeutics news, CMO Harold Bernstein sold 45,000 shares of the stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the transaction, the insider owned 10,503 shares of the company’s stock, valued at $426,001.68. The trade was a 87.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 245,000 shares of company stock worth $10,504,792 over the last quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Maze Therapeutics during the first quarter worth $57,000. Goldman Sachs Group Inc. purchased a new position in shares of Maze Therapeutics in the first quarter valued at $145,000. Rhumbline Advisers purchased a new position in shares of Maze Therapeutics in the first quarter valued at $80,000. Geode Capital Management LLC raised its stake in shares of Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after purchasing an additional 18,773 shares during the period. Finally, Ensign Peak Advisors Inc bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $227,000.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised near‑term EPS estimates across 2026–2029 and boosted FY2030 to $1.00 while maintaining a “Buy” rating and a $110 price target — a strong analyst endorsement that supports upside if development and regulatory paths stay on track. HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00
• Positive Sentiment: BTIG issued a “Buy” rating, adding further sell‑side support that could attract buyers looking for durable conviction from institutional analysts. Maze Therapeutics (NASDAQ:MAZE) Earns “Buy” Rating from BTIG Research
• Positive Sentiment: Phase 2 HORIZON data for MZE829 showed a clinically meaningful ~35.6% mean reduction in proteinuria (uACR), exceeding the ≥30% threshold cited for regulatory relevance — the fundamental clinical readout supports a pathway toward a pivotal trial. Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
• Neutral Sentiment: Technical metrics show the stock moved into oversold territory after the selloff, and some analysts/technicals argue the decline may have exhausted short‑term sellers — this could set up a technical bounce independent of fundamentals. After Plunging 30.8% in 4 Weeks, Here’s Why the Trend Might Reverse for Maze Therapeutics
• Negative Sentiment: Despite positive efficacy, the market treated the Phase 2 results as “mixed” on endpoints/subgroup/readout detail, triggering a steep selloff that wiped nearly a third of market value — heightened volatility and investor uncertainty remain key near‑term risks. Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
• Negative Sentiment: A shareholder law firm (Johnson Fistel) has opened an investigation into potential claims related to MAZE disclosures — this introduces legal/PR risk and could prolong downward pressure if it results in litigation or heightened scrutiny. MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel
• Negative Sentiment: Media coverage captured the paradox of “best‑in‑class potential” commentary alongside a sharp post‑readout plunge, amplifying sentiment swings and increasing short‑term trading risk. After ph. 2 readout, analysts herald best‑in‑class potential as stock plummets

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.